Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy

Okaji, Yurai; Tsuno, Nelson H.; Tanaka, Minoru; Yoneyama, Satomi; Matsuhashi, Mika; Kitayama, Joji; Saito, Shinsuke; Nagura, Yutaka; Tsuchiya, Takeshi; Yamada, Jun; Tanaka, Junichiro; Yoshikawa, Naoyuki; Nishikawa, Takeshi; Shuno, Yasutaka; Todo, Tomoki; Saito, Nobuhito; Takahashi, Koki; Nagawa, Hirokazu

doi:10.1016/j.ejca.2007.10.018

Cited by 43 publications

(41 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a previous report [12,13], we demonstrated the potential anti-angiogenic/anti-vasculogenic effect of SUL, which was dependent on the induction of vascular endothelial cells/EPCs apoptosis. In our lab, the new anti-angiogenic tumor vaccine, based on human umbilical vein endothelial cells (HUVECs), has been developed [16], and is being tested in clinical settings [17], with promising results in malignant brain tumors. Therefore, the anti-angiogenic strategy is promising for the treatment of solid tumors, but the presently developed modalities are not enough to completely eradicate the tumor.…”

Section: Introductionmentioning

confidence: 99%

The inhibition of autophagy potentiates anti-angiogenic effects of sulforaphane by inducing apoptosis

et al. 2010

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

The inhibition of autophagy potentiates anti-angiogenic effects of sulforaphane by inducing apoptosis

et al. 2010

Self Cite

View full text Add to dashboard Cite

show abstract

“…In a pilot study conducted by Okaji et al, patients who had recurrence of their brain tumors or metastatic colorectal cancer were treated with glutaraldehyde-fixed HUVECs by intradermal injection. Specific cellular immune responses against HUVECs were detected, and partial or complete tumor responses for at least 9 months were shown in three patients with malignant brain tumors (Okaji et al 2008).…”

Section: Introductionmentioning

confidence: 99%

Fusion with human lung cancer cells elongates the life span of human umbilical endothelial cells and enhances the anti-tumor immunity

Fang

Zhou

et al. 2015

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Moreover, many studies have successfully used exogenous or allogeneic ECs as vaccines to inhibit the growth of tumors in experimental models (9)(10)(11)(12). Recently, a pilot study using human umbili-www.bjournal.com.br Braz J Med Biol Res 44 (2) 2011 cal vein endothelial cells (HUVECs) as a vaccine to treat cancer patients with brain tumors achieved promising results (13), underscoring the clinical importance of such study. However, there are still no reports on immunization with HUVECs to treat prostatic carcinoma.…”

mentioning

confidence: 97%

Enhanced inhibition of murine prostatic carcinoma growth by immunization with or administration of viable human umbilical vein endothelial cells and CRM197

Zhang

Didier

et al. 2011

Braz J Med Biol Res

View full text Add to dashboard Cite

Vaccination with xenogeneic and syngeneic endothelial cells is effective for inhibiting tumor growth. Nontoxic diphtheria toxin (CRM197), as an immunogen or as a specific inhibitor of heparin-binding EGF-like growth factor, has shown promising antitumor activity. Therefore, immunization with or administration of viable human umbilical vein endothelial cells (HUVECs) combined with CRM197 could have an enhanced antitumor effect. Six-week-old C57BL/6J male mice were vaccinated with viable HUVECs, 1 x 10 6 viable HUVECs combined with 100 μg CRM197, or 100 μg CRM197 alone by ip injections once a week for 4 consecutive weeks. RM-1 cells (5 x 10 5 ) were inoculated by sc injection as a preventive procedure. During the therapeutic procedure, 6-week-old male C57BL/6J mice were challenged with 1 x 10 5 RM-1 cells, then injected sc with 1 x 10 6 viable HUVECs, 1 x 10 6 viable HUVECs + 100 μg CRM197, and 100 μg CRM197 alone twice a week for 4 consecutive weeks. Tumor volume and life span were monitored. We also investigated the effects of immunization with HUVECs on the aortic arch wall and on wound healing. Vaccination with or administration of viable HUVECs+CRM197 enhanced the inhibition of RM-1 prostatic carcinoma by 24 and 29%, respectively, and prolonged the life span for 3 and 4 days, respectively, compared with those of only vaccination or administration with viable HUVECs of tumor-bearing C57BL/6J mice. Furthermore, HUVEC immunization caused some damage to the aortic arch wall but did not have remarkable effects on the rate of wound healing; the wounds healed in approximately 13 days. Treatment with CRM197 in combination with viable HUVECs resulted in a marked enhancement of the antitumor effect in the preventive or therapeutic treatment for prostatic carcinoma in vivo, suggesting a novel combination for anti-cancer therapy.

show abstract

Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy

Cited by 43 publications

References 33 publications

The inhibition of autophagy potentiates anti-angiogenic effects of sulforaphane by inducing apoptosis

The inhibition of autophagy potentiates anti-angiogenic effects of sulforaphane by inducing apoptosis

Fusion with human lung cancer cells elongates the life span of human umbilical endothelial cells and enhances the anti-tumor immunity

Enhanced inhibition of murine prostatic carcinoma growth by immunization with or administration of viable human umbilical vein endothelial cells and CRM197

Contact Info

Product

Resources

About